Last updated: July 31, 2026
Ampicillin sodium is an established generic injectable beta-lactam antibiotic with no meaningful composition-of-matter exclusivity, no active branded innovation cycle, and limited standalone clinical-development activity. Its commercial value is tied to hospital procurement, neonatal and maternal infection protocols, susceptibility patterns, manufacturing reliability, and periodic injectable-antibiotic shortages. Market growth is likely to remain low in mature markets, while demand will be more resilient in hospital systems that require low-cost parenteral treatment for serious bacterial infections.
What is the current FDA status of ampicillin sodium?
Ampicillin sodium is an FDA-approved injectable formulation of ampicillin, a semisynthetic penicillin in the aminopenicillin class. It is administered intravenously or intramuscularly after reconstitution.
The FDA-approved label covers susceptible infections involving:
- Respiratory tract infections
- Genitourinary tract infections
- Gastrointestinal infections
- Skin and soft-tissue infections
- Meningitis and septicemia
- Infections caused by susceptible streptococci, enterococci, non-beta-lactamase-producing staphylococci, Haemophilus influenzae, Escherichia coli, Proteus mirabilis, and other labeled organisms
Ampicillin sodium is not stable against beta-lactamases produced by many resistant organisms. It is therefore not interchangeable with ampicillin-sulbactam, piperacillin-tazobactam, or carbapenems.
The product remains a prescription hospital antibiotic. FDA approval covers multiple generic injectable products supplied by manufacturers through abbreviated new drug applications, or ANDAs. The reference product and generic products are subject to current good manufacturing practice, sterile-manufacturing, labeling, potency, and stability requirements.
What dosage forms are marketed?
The primary commercial dosage form is sterile powder for injection in single-dose vials. Common strengths include:
| Strength |
Typical use context |
| 125 mg vial |
Pediatric dosing and selected neonatal applications |
| 250 mg vial |
Pediatric and lower-dose hospital use |
| 500 mg vial |
Adult and pediatric dosing |
| 1 g vial |
Adult inpatient treatment |
| 2 g vial |
Higher-dose adult treatment and severe infections |
Availability varies by manufacturer, hospital contract, national market, and shortage conditions. Ampicillin sodium differs from oral ampicillin trihydrate and from ampicillin-sulbactam injection.
What clinical trials are evaluating ampicillin sodium?
Ampicillin sodium is not undergoing a conventional late-stage development program for a new indication. Its current clinical-trial role is mainly as a standard-of-care comparator, empiric therapy, protocol component, or background antibiotic.
ClinicalTrials.gov searches identify studies involving ampicillin in several recurring areas:
Neonatal sepsis and meningitis
Ampicillin remains a standard component of empiric treatment for suspected early-onset neonatal sepsis, often combined with gentamicin. It is also used in neonatal meningitis regimens when susceptible organisms are suspected.
Clinical research in this area generally evaluates:
- Duration of empiric antibiotic therapy
- Biomarker-guided discontinuation
- Antibiotic stewardship in newborns
- Early-onset sepsis risk assessment
- Maternal intrapartum antibiotic exposure
- Outcomes associated with ampicillin-gentamicin protocols
The trial objective usually concerns treatment duration, diagnostic algorithms, or neonatal outcomes rather than a new ampicillin formulation.
Maternal group B streptococcal prophylaxis
Penicillin G is generally preferred for intrapartum group B streptococcal prophylaxis, but ampicillin may appear in obstetric protocols when clinically appropriate or when trial investigators compare hospital treatment pathways.
This use is clinically important but does not create meaningful new product exclusivity because the active ingredient and route are long established.
Enterococcal infections
Ampicillin is a principal treatment option for susceptible Enterococcus faecalis infections, including selected endocarditis cases. Clinical studies may evaluate ampicillin in combination with ceftriaxone, gentamicin, or other agents.
The main research questions concern:
- Combination therapy
- Renal toxicity
- Treatment duration
- Relapse rates
- Outcomes in older or medically complex patients
- Management of ampicillin-susceptible enterococcal bacteremia
Intra-abdominal and urinary infections
Ampicillin may be used when culture results confirm susceptibility. Trial activity in these areas is limited because broader-spectrum agents and targeted oral therapies often occupy the commercial and clinical-development focus.
What is the clinical-trial outlook?
The clinical outlook is stable rather than expansionary. Ampicillin sodium is likely to continue appearing in investigator-led studies and antimicrobial-stewardship trials, but it is unlikely to generate a new branded indication, premium pricing, or substantial trial-driven market expansion.
How many patents cover ampicillin sodium?
No active composition-of-matter patent is expected to protect ampicillin sodium in the United States. Ampicillin was introduced in the 1960s, and the core molecule entered the public domain decades ago.
The relevant intellectual-property position is:
| IP category |
Current commercial relevance |
| Ampicillin composition patent |
Expired |
| Ampicillin sodium injectable formulation |
Generally generic and off-patent |
| Basic antibacterial method-of-use claims |
Expired or commercially weak |
| New combination therapy claims |
Potentially relevant only to the specific combination |
| Manufacturing-process patents |
Possible at the supplier level, but not a barrier to ordinary generic entry |
| Device or packaging patents |
Limited relevance because the product is generally a vial-based injectable |
| Regulatory exclusivity |
No meaningful current exclusivity expected for the established generic product |
The Orange Book remains the principal FDA source for approved drug products and listed patent information. Patent status can differ by specific application, applicant, strength, and product configuration, so an Orange Book review should be conducted at the product level rather than by active ingredient alone (FDA, 2024a).
What formulation patents protect ampicillin sodium?
There is no widely recognized active formulation-patent estate that materially blocks generic ampicillin sodium injection in the United States. Generic suppliers compete primarily on:
- Sterile manufacturing capacity
- Container-closure systems
- Reconstitution stability
- Shelf life
- Contract pricing
- Quality history
- Supply continuity
- Hospital purchasing agreements
A company could obtain patents on a specialized premix, ready-to-use presentation, stability-enhancing excipient system, or delivery device. Such claims would protect the specific presentation, not the underlying ampicillin sodium molecule.
When does ampicillin sodium lose exclusivity?
Ampicillin sodium has already lost market exclusivity. The product is a mature generic antibiotic and does not have a current U.S. exclusivity date comparable to a newly approved small molecule.
The commercial exclusivity timeline is:
| Milestone |
Approximate status |
| Ampicillin introduced |
1960s |
| Core patent protection |
Expired decades ago |
| Generic injectable competition |
Established |
| Current U.S. regulatory position |
Multiple generic products and ANDAs |
| Expected loss of exclusivity |
Already occurred |
| New generic-entry event |
Not applicable to the active ingredient |
The principal commercial risk is not patent expiry. It is supplier withdrawal, manufacturing interruption, raw-material constraints, quality actions, or hospital substitution.
Are there Paragraph IV challenges involving ampicillin sodium?
Paragraph IV litigation is not a central issue for ampicillin sodium. Paragraph IV certifications generally arise when a generic applicant challenges patents listed for a branded reference product. Because ampicillin sodium is a long-established generic injectable, there is no apparent current branded patent barrier that would support a major Paragraph IV campaign.
Potential disputes could still arise over:
- A new injectable presentation
- A fixed-dose combination
- A ready-to-administer formulation
- A new delivery device
- A patented manufacturing process
- A later-developed ampicillin combination product
Those disputes would concern the newer product or process, not the basic ampicillin sodium injection.
What is the Orange Book status of ampicillin sodium?
Ampicillin sodium products appear in FDA-approved drug-product databases through reference and generic approvals. The Orange Book provides application-level information, therapeutic-equivalence determinations, patent listings, and exclusivity data where applicable.
For procurement and litigation analysis, the relevant checks are:
- Identify the specific injectable strength.
- Confirm whether the product is an NDA reference product or an ANDA.
- Review therapeutic-equivalence coding.
- Check current patent listings for the exact application.
- Verify whether the product is active, discontinued, or subject to a regulatory action.
- Review FDA shortage information independently from the Orange Book.
Because the market is generic, product availability can change without a patent event.
What patent litigation affects ampicillin sodium?
No major current U.S. patent-litigation trend is associated with basic ampicillin sodium injection. The product's litigation exposure is low relative to newer antibiotics, long-acting injectables, and combination products.
The more relevant legal issues are:
- Manufacturing-quality investigations
- Sterility failures
- Product recalls
- Contract disputes
- Antitrust claims involving hospital purchasing
- Supply allocation
- False or misleading labeling claims
- Litigation concerning newer beta-lactam combinations
These matters may affect supply or reputation but do not create a new patent moat around ampicillin sodium.
Which companies compete in the ampicillin sodium market?
Competition is fragmented across generic injectable manufacturers, hospital suppliers, and contract manufacturers. The product may be supplied by companies such as Pfizer or other approved generic manufacturers depending on the country, strength, and period reviewed. Product ownership and availability can change through licensing, divestitures, discontinuations, and manufacturing transfers.
The competitive basis is operational rather than scientific:
| Competitive factor |
Importance |
| FDA-compliant sterile capacity |
Very high |
| Reliable vial supply |
Very high |
| Hospital group-purchasing contracts |
High |
| Cost of goods |
High |
| Shortage resilience |
High |
| Brand differentiation |
Low |
| Patent protection |
Low |
| Clinical novelty |
Low |
Ampicillin sodium can receive price support when few suppliers remain active. That support is usually temporary and depends on supply conditions.
What is the market size and revenue outlook for ampicillin sodium?
Public market-research reports often combine ampicillin sodium with oral ampicillin, ampicillin-sulbactam, or broader penicillin-injection categories. Standalone global revenue figures are therefore inconsistent and should not be treated as audited market data.
A practical market model is:
- Mature-market volume: stable to declining
- Unit pricing: low, with episodic increases during shortages
- Hospital demand: persistent
- Retail demand: limited because injectable use is concentrated in institutional care
- Emerging-market demand: potentially higher due to lower-cost treatment protocols
- Innovation premium: minimal
- Long-term revenue growth: low single digit in a favorable supply environment, with volatility from shortages
Base-case projection, 2024-2030
| Scenario |
Volume trend |
Price trend |
Revenue outcome |
| Bear case |
Decline of 2%-4% annually |
Flat to modest increase |
Low-single-digit annual decline |
| Base case |
Flat to 2% annual growth |
1%-3% annual increase |
Approximately 1%-4% annual growth |
| Upside case |
2%-4% annual growth |
3%-6% increase during constrained supply |
Approximately 5%-9% annual growth |
These are analytical scenarios, not reported market forecasts. The base case assumes continued neonatal, maternal, enterococcal, and hospital empiric use; stable generic competition; and no sustained global manufacturing disruption.
What generic entry risks exist for ampicillin sodium?
Generic-entry risk is already realized. Additional entrants can reduce pricing, but the market may not attract large numbers of new suppliers because injectable antibiotics require:
- Validated sterile facilities
- High regulatory compliance
- Reliable active pharmaceutical ingredient supply
- Stability data
- Commercial-scale fill-finish capacity
- Hospital-contract access
- Working capital for low-margin products
The key risk is therefore two-sided. More generic suppliers can depress price, while supplier exits can create shortages and pricing spikes.
How strong is the patent estate for ampicillin sodium?
The patent estate is weak for the base product and does not support premium valuation based on exclusivity.
| Factor |
Assessment |
| Composition-of-matter protection |
None expected |
| Core injectable formulation protection |
Weak or expired |
| Method-of-use protection |
Limited and generally expired |
| Manufacturing IP |
Potentially relevant to individual suppliers |
| Regulatory exclusivity |
None of strategic importance |
| Litigation leverage |
Low |
| Freedom to operate for standard injection |
Broad |
| Commercial moat |
Supply chain and contracts, not patents |
A new entrant should focus its diligence on FDA product approval, manufacturing inspection history, drug-shortage records, API sourcing, and hospital contracting rather than patent clearance.
How does ampicillin sodium compare with competing antibiotics?
| Product |
Main advantage |
Main limitation |
Commercial position |
| Ampicillin sodium |
Low cost, established efficacy, neonatal and enterococcal utility |
Beta-lactamase vulnerability, frequent dosing |
Mature generic |
| Ampicillin-sulbactam |
Beta-lactamase inhibition and broader coverage |
Higher cost and supply variability |
Generic hospital product |
| Penicillin G |
Preferred for selected streptococcal and syphilis indications |
Narrower spectrum |
Mature generic |
| Piperacillin-tazobactam |
Broad gram-negative and anaerobic coverage |
Higher cost and resistance concerns |
Hospital broad-spectrum standard |
| Ceftriaxone |
Convenient once-daily dosing |
Limited enterococcal activity |
High-volume generic |
| Meropenem |
Broad activity against resistant organisms |
Stewardship and cost concerns |
Reserve therapy |
Ampicillin remains competitive where susceptibility is known or where neonatal and enterococcal protocols favor it. It is less competitive as an empiric adult therapy in settings with high beta-lactamase or resistant gram-negative prevalence.
Is there biosimilar risk for ampicillin sodium?
There is no biosimilar risk. Ampicillin sodium is a chemically synthesized small-molecule antibiotic, not a biologic. Competitive entry occurs through generic-drug pathways, primarily ANDAs in the United States, rather than biosimilar applications under the Biologics Price Competition and Innovation Act.
What manufacturing and geographic barriers affect the product?
The principal geographic barrier is not patent coverage. It is regulatory and manufacturing execution.
United States
The market depends on FDA-approved sterile facilities, ANDA approval, product availability, and hospital purchasing contracts. FDA drug-shortage monitoring is commercially important because injectable anti-infectives can experience temporary supply constraints (FDA, 2024b).
Europe
European products are governed through national and decentralized procedures, with procurement often occurring through tenders. Pricing pressure is generally stronger than in the United States, while supply continuity can influence tender outcomes.
Emerging markets
Demand may be supported by affordability and public-sector hospital procurement. Risks include variable quality standards, local registration requirements, API dependence, and inconsistent cold-chain or distribution infrastructure where applicable.
What licensing deals affect ampicillin sodium?
No major current licensing transaction is required to commercialize standard ampicillin sodium injection. Licensing may arise through:
- Contract manufacturing
- Regional distribution rights
- Technology transfer
- API supply agreements
- Hospital formulary partnerships
- Portfolio acquisitions involving generic injectables
These arrangements typically concern manufacturing and distribution economics rather than proprietary drug science.
Key Takeaways
- Ampicillin sodium is an established generic injectable antibiotic with no meaningful current composition-of-matter exclusivity.
- Clinical-trial activity is mainly investigator-led and protocol-based, particularly in neonatal sepsis, maternal care, and enterococcal infections.
- No major Paragraph IV or patent-litigation event defines the current market.
- The Orange Book is relevant for product-level approval and patent verification, but the base product has limited patent protection.
- Biosimilar risk does not apply because ampicillin sodium is a small-molecule drug.
- Market performance depends on sterile-manufacturing capacity, hospital contracts, shortages, and susceptibility-driven prescribing.
- A reasonable 2024-2030 base-case revenue outlook is approximately 1%-4% annual growth, with higher short-term pricing during supply disruptions.
- The strongest commercial moat is reliable supply, not intellectual property.
FAQs
Is ampicillin sodium still used in neonatal intensive-care units?
Yes. It remains a standard empiric component for suspected neonatal bacterial sepsis, commonly combined with gentamicin, subject to local resistance patterns and clinical protocols.
Is ampicillin sodium interchangeable with ampicillin-sulbactam?
No. Ampicillin-sulbactam contains a beta-lactamase inhibitor and has a different antimicrobial spectrum, labeling profile, dosing framework, and product identity.
Can a company obtain a new patent on ampicillin sodium?
A patent on the old molecule itself is not available. A company may pursue claims covering a new formulation, premix, delivery system, stability profile, manufacturing process, or combination, subject to novelty and non-obviousness requirements.
Does ampicillin sodium have a branded premium market?
Generally no. Standard ampicillin sodium injection is a commodity-like hospital generic. Premium pricing is more likely during temporary shortages or for differentiated ready-to-use presentations.
What is the biggest investment risk in ampicillin sodium?
The largest risks are sterile-manufacturing failure, API disruption, hospital-contract loss, regulatory action, and substitution by broader-spectrum or more convenient antibiotics.
References
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2024b). FDA drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov: Ampicillin studies. https://clinicaltrials.gov/search?term=ampicillin
-
U.S. Food and Drug Administration. (2023). Ampicillin for injection prescribing information. FDA labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
World Health Organization. (2023). WHO AWaRe antibiotic book. World Health Organization. https://www.who.int/publications/i/item/9789240062382
